Details of the Drug Combination

General Information of Drug Combination (ID: DCLMATY)

• Drug Combination Name: Crizotinib + Bortezomib
• Indication: Clear cell renal cell carcinoma; Status: Investigative [1]
• Component Drugs:
  Crizotinib (DM4F29C): Small molecular drug
  Bortezomib (DMNO38U): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: 786-0
  Zero Interaction Potency (ZIP) Score: 1.62
  Bliss Independence Score: 5.59
  Loewe Additivity Score: 5.89
  LHighest Single Agent (HSA) Score: 5.85

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Crizotinib

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[2]

Crizotinib Interacts with 4 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Modulator	[4]
ALK tyrosine kinase receptor (ALK)	TTPMQSO	ALK_HUMAN	Modulator	[4]
Proto-oncogene c-Ros (ROS1)	TTSZ6Y3	ROS1_HUMAN	Modulator	[4]
HGF/Met signaling pathway (HGF/Met pathway)	TTKA5LP	NOUNIPROTAC	Inhibitor	[9]

Crizotinib Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[11]

Crizotinib Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[12]

Crizotinib Interacts with 45 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[13]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Activity	[14]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Increases Response To Substance	[7]
ALK tyrosine kinase receptor (ALK)	OTV3P4V8	ALK_HUMAN	Decreases Response To Substance	[15]
Prominin-1 (PROM1)	OTBHV8NX	PROM1_HUMAN	Decreases Expression	[6]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Decreases Expression	[6]
Epithelial cell adhesion molecule (EPCAM)	OTHBZK5X	EPCAM_HUMAN	Decreases Expression	[6]
Cytidine deaminase (CDA)	OT3HXP6N	CDD_HUMAN	Decreases Expression	[6]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Increases Expression	[16]
Acyl-CoA 6-desaturase (FADS2)	OTUX531P	FADS2_HUMAN	Increases Expression	[16]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Increases Expression	[16]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[16]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[16]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[16]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)	OTCO26FV	HMCS1_HUMAN	Increases Expression	[16]
Sterol regulatory element-binding protein 2 (SREBF2)	OTBXUNPL	SRBP2_HUMAN	Increases Expression	[16]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[16]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Increases Phosphorylation	[16]
Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)	OT6KFNMS	CAC1C_HUMAN	Decreases Activity	[16]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Decreases Activity	[16]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[7]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Expression	[7]
Follitropin subunit beta (FSHB)	OTGLS283	FSHB_HUMAN	Decreases Secretion	[17]
Lutropin subunit beta (LHB)	OT5GBOVJ	LSHB_HUMAN	Decreases Secretion	[17]
Tyrosine-protein kinase Lck (LCK)	OT883FG9	LCK_HUMAN	Decreases Activity	[18]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[19]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[20]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Phosphorylation	[19]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Increases Secretion	[21]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Phosphorylation	[22]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Phosphorylation	[22]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Phosphorylation	[23]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Phosphorylation	[24]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1)	OTZRWTGA	IQGA1_HUMAN	Decreases Phosphorylation	[25]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Decreases Phosphorylation	[24]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[7]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Cleavage	[26]
Echinoderm microtubule-associated protein-like 4 (EML4)	OTJC45TA	EMAL4_HUMAN	Increases Mutagenesis	[22]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Decreases Activity	[14]
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Decreases Response To Substance	[27]
Pro-epidermal growth factor (EGF)	OTANRJ0L	EGF_HUMAN	Decreases Response To Substance	[23]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Response To Substance	[27]
Mast/stem cell growth factor receptor Kit (KIT)	OTHUY3VZ	KIT_HUMAN	Decreases Response To Substance	[15]
Proheparin-binding EGF-like growth factor (HBEGF)	OTLU00JS	HBEGF_HUMAN	Decreases Response To Substance	[23]
Protransforming growth factor alpha (TGFA)	OTPD1LL9	TGFA_HUMAN	Decreases Response To Substance	[23]

Indication(s) of Bortezomib

Disease Entry	ICD 11	Status	REF
Leukemia	N.A.	Approved	[3]
Lung cancer	2C25.0	Approved	[3]
Lymphoproliferative syndrome	N.A.	Approved	[3]
MALT lymphoma	N.A.	Approved	[3]
Mantle cell lymphoma	2A85.5	Approved	[4]
Minimally invasive lung adenocarcinoma	N.A.	Approved	[3]
Multiple myeloma	2A83	Approved	[5]
Nodal marginal zone lymphoma	2A85.0	Approved	[3]
Plasma cell myeloma	2A83.1	Approved	[3]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[3]
Non-hodgkin lymphoma	2B33.5	Phase 3	[5]
B-cell neoplasm	N.A.	Investigative	[3]
Colon cancer	2B90.Z	Investigative	[3]
Gastric cancer	2B72	Investigative	[3]

Bortezomib Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Cationic trypsinogen (PRSS1)	TT2WR1T	TRY1_HUMAN	Inhibitor	[34]
Kallikrein-related peptidase (KLK)	TT5L2VC	NOUNIPROTAC	Inhibitor	[34]
Proteasome (PS)	TTU7ZMG	NOUNIPROTAC	Modulator	[35]

Bortezomib Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[36]

Bortezomib Interacts with 5 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[37]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[38]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[39]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[40]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[39]

Bortezomib Interacts with 686 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Expression	[41]
Extended synaptotagmin-2 (ESYT2)	OTWCXTX3	ESYT2_HUMAN	Decreases Expression	[28]
Alternative prion protein (PRNP)	OTE85L1Q	APRIO_HUMAN	Increases Expression	[28]
Serine/threonine-protein kinase Sgk1 (SGK1)	OT301T1U	SGK1_HUMAN	Increases Expression	[28]
Cytosolic acyl coenzyme A thioester hydrolase (ACOT7)	OT7C68YV	BACH_HUMAN	Decreases Expression	[28]
GTP-binding protein 1 (GTPBP1)	OTA9KV6C	GTPB1_HUMAN	Decreases Expression	[28]
Galectin-8 (LGALS8)	OT71LJ8T	LEG8_HUMAN	Increases Expression	[28]
26S proteasome non-ATPase regulatory subunit 12 (PSMD12)	OTWICA51	PSD12_HUMAN	Increases Expression	[28]
Leukocyte-specific transcript 1 protein (LST1)	OTUVG424	LST1_HUMAN	Decreases Expression	[28]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Decreases Expression	[28]
Krev interaction trapped protein 1 (KRIT1)	OT58AP1I	KRIT1_HUMAN	Increases Expression	[28]
Beta-1,3-N-acetylglucosaminyltransferase manic fringe (MFNG)	OTUX45ZF	MFNG_HUMAN	Decreases Expression	[28]
Pirin (PIR)	OT8ALXHU	PIR_HUMAN	Increases Expression	[28]
Pyridoxal kinase (PDXK)	OT40AJ5J	PDXK_HUMAN	Increases Expression	[28]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Decreases Expression	[28]
Suppressor of cytokine signaling 3 (SOCS3)	OTY183WJ	SOCS3_HUMAN	Increases Expression	[28]
TRAF-type zinc finger domain-containing protein 1 (TRAFD1)	OT7AU2R3	TRAD1_HUMAN	Increases Expression	[28]
Cytoplasmic dynein 1 intermediate chain 1 (DYNC1I1)	OTFX1KCG	DC1I1_HUMAN	Increases Expression	[28]
Chromodomain-helicase-DNA-binding protein 2 (CHD2)	OTRKL6YC	CHD2_HUMAN	Increases Expression	[28]
Golgi SNAP receptor complex member 2 (GOSR2)	OTYHIYN2	GOSR2_HUMAN	Increases Expression	[28]
Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	OTOKUXUH	ADA10_HUMAN	Decreases Expression	[28]
Apolipoprotein L1 (APOL1)	OT8QBVTY	APOL1_HUMAN	Increases Expression	[28]
Interferon-inducible protein AIM2 (AIM2)	OT86QUI8	AIM2_HUMAN	Increases Expression	[28]
Myosin regulatory light chain 12B (MYL12B)	OTXMLQOT	ML12B_HUMAN	Increases Expression	[28]
Centrosomal protein of 290 kDa (CEP290)	OTVN52VH	CE290_HUMAN	Increases Expression	[28]
Small ribosomal subunit protein uS12m (MRPS12)	OTGY4GIX	RT12_HUMAN	Decreases Expression	[28]
UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit (OGT)	OT1Z1ZXE	OGT1_HUMAN	Decreases Expression	[28]
V-type proton ATPase subunit e 1 (ATP6V0E1)	OTZZIUYY	VA0E1_HUMAN	Increases Expression	[28]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Decreases Expression	[28]
Transcription factor MafG (MAFG)	OTBQFUZH	MAFG_HUMAN	Increases Expression	[28]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2)	OT6Y1QZN	IRAK2_HUMAN	Increases Expression	[28]
PHD finger protein 1 (PHF1)	OTW2PSIR	PHF1_HUMAN	Increases Expression	[28]
Synaptogyrin-2 (SYNGR2)	OTJX84RI	SNG2_HUMAN	Decreases Expression	[28]
Cytohesin-interacting protein (CYTIP)	OTRJ3ZC5	CYTIP_HUMAN	Increases Expression	[28]
Growth arrest-specific protein 7 (GAS7)	OT0M5TNY	GAS7_HUMAN	Decreases Expression	[28]
F-box-like/WD repeat-containing protein TBL1X (TBL1X)	OTXQ51E0	TBL1X_HUMAN	Increases Expression	[28]
Glycosaminoglycan xylosylkinase (FAM20B)	OTOA0UYT	XYLK_HUMAN	Decreases Expression	[28]
Suppressor of cytokine signaling 5 (SOCS5)	OTN1ABYR	SOCS5_HUMAN	Increases Expression	[28]
Protein tyrosine phosphatase type IVA 3 (PTP4A3)	OTXMMWUN	TP4A3_HUMAN	Decreases Expression	[28]
Deformed epidermal autoregulatory factor 1 homolog (DEAF1)	OTCLX3ZW	DEAF1_HUMAN	Decreases Expression	[28]
Calpain-15 (CAPN15)	OT0WE161	CAN15_HUMAN	Decreases Expression	[28]
Carbonyl reductase 3 (CBR3)	OT9G6SF0	CBR3_HUMAN	Increases Expression	[28]
Triple functional domain protein (TRIO)	OT71X1AK	TRIO_HUMAN	Decreases Expression	[28]
Cystatin-F (CST7)	OTQWZUVQ	CYTF_HUMAN	Increases Expression	[28]
ATP-dependent DNA helicase Q4 (RECQL4)	OT59LSW7	RECQ4_HUMAN	Increases Expression	[28]
Erlin-2 (ERLIN2)	OT551BVG	ERLN2_HUMAN	Decreases Expression	[28]
Pre-mRNA-processing factor 6 (PRPF6)	OT3U0ABN	PRP6_HUMAN	Decreases Expression	[28]
Lysine-specific demethylase 4B (KDM4B)	OT5P1UPY	KDM4B_HUMAN	Decreases Expression	[28]
Methyl-CpG-binding domain protein 4 (MBD4)	OTWR9YXE	MBD4_HUMAN	Increases Expression	[28]
Arginyl-tRNA--protein transferase 1 (ATE1)	OT3QNM39	ATE1_HUMAN	Increases Expression	[28]
GDH/6PGL endoplasmic bifunctional protein (H6PD)	OTO7TNDD	G6PE_HUMAN	Decreases Expression	[28]
NAD kinase (NADK)	OTYN9GX0	NADK_HUMAN	Decreases Expression	[28]
AP-2 complex subunit alpha-1 (AP2A1)	OTEFZB21	AP2A1_HUMAN	Decreases Expression	[28]
Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4)	OTBMJUOC	M4K4_HUMAN	Increases Expression	[28]
Acyl-CoA 6-desaturase (FADS2)	OTUX531P	FADS2_HUMAN	Decreases Expression	[28]
Phosphatidylserine lipase ABHD16A (ABHD16A)	OTDS9K1Z	ABHGA_HUMAN	Increases Expression	[28]
G patch domain and ankyrin repeat-containing protein 1 (GPANK1)	OT1TN2KT	GPAN1_HUMAN	Increases Expression	[28]
Putative lipid scramblase CLPTM1 (CLPTM1)	OT14QP7N	CLPT1_HUMAN	Decreases Expression	[28]
Glutathione reductase, mitochondrial (GSR)	OTM2TUYM	GSHR_HUMAN	Increases Expression	[28]
HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)	OT7KZMP2	DRA_HUMAN	Decreases Expression	[28]
Myelin basic protein (MBP)	OTFZCEDB	MBP_HUMAN	Decreases Expression	[28]
Thy-1 membrane glycoprotein (THY1)	OTVONVTB	THY1_HUMAN	Decreases Expression	[28]
HLA class II histocompatibility antigen, DP beta 1 chain (HLA-DPB1)	OTW8JHU2	DPB1_HUMAN	Decreases Expression	[28]
T-cell surface glycoprotein CD5 (CD5)	OTC5JEG5	CD5_HUMAN	Decreases Expression	[28]
Alpha-galactosidase A (GLA)	OTBSR6DT	AGAL_HUMAN	Increases Expression	[28]
HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA)	OTZE5Q7R	DOA_HUMAN	Decreases Expression	[28]
Cathepsin D (CTSD)	OTQZ36F3	CATD_HUMAN	Increases Expression	[28]
Trypsin-2 (PRSS2)	OTOMVUWL	TRY2_HUMAN	Decreases Expression	[28]
Prosaposin (PSAP)	OTUOEKY7	SAP_HUMAN	Increases Expression	[28]
Guanine nucleotide-binding protein G(i) subunit alpha-3 (GNAI3)	OT89UWAR	GNAI3_HUMAN	Increases Expression	[28]
Steryl-sulfatase (STS)	OTXTJQPC	STS_HUMAN	Decreases Expression	[28]
Monoacylglycerol lipase ABHD2 (ABHD2)	OTCRUOCS	ABHD2_HUMAN	Increases Expression	[28]
Gamma-enolase (ENO2)	OTRODL0T	ENOG_HUMAN	Increases Expression	[28]
Tropomyosin alpha-1 chain (TPM1)	OTD73X6R	TPM1_HUMAN	Increases Expression	[28]
Cancer/testis antigen family 45 member A6 (CT45A5)	OTIFETOM	CT456_HUMAN	Increases Expression	[28]
Schwannomin-interacting protein 1 (SCHIP1)	OTF3FR4A	SCHI1_HUMAN	Decreases Expression	[28]
Granzyme B (GZMB)	OTPPVIRS	GRAB_HUMAN	Increases Expression	[28]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Increases Expression	[28]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Increases Expression	[28]
Phenylethanolamine N-methyltransferase (PNMT)	OTGLCPE8	PNMT_HUMAN	Decreases Expression	[28]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)	OT2HZK5M	GTR3_HUMAN	Increases Expression	[28]
Ras-related protein Ral-A (RALA)	OT734R7X	RALA_HUMAN	Increases Expression	[28]
Breakpoint cluster region protein (BCR)	OTCN76C1	BCR_HUMAN	Decreases Expression	[28]
Glucose-6-phosphate 1-dehydrogenase (G6PD)	OT300SMK	G6PD_HUMAN	Decreases Expression	[28]
Steroid hormone receptor ERR1 (ESRRA)	OTTDTUSP	ERR1_HUMAN	Decreases Expression	[28]
B-cell antigen receptor complex-associated protein alpha chain (CD79A)	OTOJC8DV	CD79A_HUMAN	Decreases Expression	[28]
Granzyme A (GZMA)	OT43R33L	GRAA_HUMAN	Decreases Expression	[28]
Cytochrome b-245 light chain (CYBA)	OT16N9ZO	CY24A_HUMAN	Decreases Expression	[28]
Sodium/potassium-transporting ATPase subunit alpha-3 (ATP1A3)	OTM8EG6H	AT1A3_HUMAN	Decreases Expression	[28]
Perforin-1 (PRF1)	OTFVXD7H	PERF_HUMAN	Decreases Expression	[28]
Insulin-degrading enzyme (IDE)	OT5GQTJ5	IDE_HUMAN	Increases Expression	[28]
Ras-related C3 botulinum toxin substrate 2 (RAC2)	OTAOHFNH	RAC2_HUMAN	Decreases Expression	[28]
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)	OT18H1B0	ERF3A_HUMAN	Decreases Expression	[28]
Folate receptor alpha (FOLR1)	OT0QZ0H6	FOLR1_HUMAN	Decreases Expression	[28]
Cyclic AMP-dependent transcription factor ATF-2 (ATF2)	OTNIZPEA	ATF2_HUMAN	Increases Expression	[28]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[28]
Immunoglobulin lambda-like polypeptide 1 (IGLL1)	OTRTNVOG	IGLL1_HUMAN	Decreases Expression	[28]
Mucin-1 (MUC1)	OTHQI7IY	MUC1_HUMAN	Decreases Expression	[28]
Ribosyldihydronicotinamide dehydrogenase (NQO2)	OTGDAJRZ	NQO2_HUMAN	Increases Expression	[28]
Leukosialin (SPN)	OTFW338K	LEUK_HUMAN	Decreases Expression	[28]
Transcription factor JunD (JUND)	OTNKACJD	JUND_HUMAN	Decreases Expression	[28]
Integrin beta-6 (ITGB6)	OTI3DJ7U	ITB6_HUMAN	Increases Expression	[28]
Ras-related protein Rab-5A (RAB5A)	OTFR2KM4	RAB5A_HUMAN	Decreases Expression	[28]
Integrin alpha-L (ITGAL)	OTCUQAIS	ITAL_HUMAN	Decreases Expression	[28]
B-cell lymphoma 3 protein (BCL3)	OT1M5B95	BCL3_HUMAN	Decreases Expression	[28]
5'-nucleotidase (NT5E)	OT7J5LT6	5NTD_HUMAN	Decreases Expression	[28]
Ephrin type-A receptor 1 (EPHA1)	OTGJMRZ0	EPHA1_HUMAN	Decreases Expression	[28]
CD9 antigen (CD9)	OT2184XU	CD9_HUMAN	Increases Expression	[28]
Integrin alpha-6 (ITGA6)	OT3FA39C	ITA6_HUMAN	Decreases Expression	[28]
Ribosomal protein S6 kinase beta-1 (RPS6KB1)	OTAELNGX	KS6B1_HUMAN	Increases Expression	[28]
Tyrosine-protein kinase JAK1 (JAK1)	OT0X3D17	JAK1_HUMAN	Decreases Expression	[28]
ER lumen protein-retaining receptor 1 (KDELR1)	OT8YBS5G	ERD21_HUMAN	Decreases Expression	[28]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[28]
Polypyrimidine tract-binding protein 1 (PTBP1)	OT2OBJUK	PTBP1_HUMAN	Decreases Expression	[28]
NKG2-D type II integral membrane protein (KLRK1)	OTQWXK71	NKG2D_HUMAN	Decreases Expression	[28]
CD82 antigen (CD82)	OTH8MC64	CD82_HUMAN	Decreases Expression	[28]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)	OT17HGXJ	DMB_HUMAN	Decreases Expression	[28]
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)	OTG0TTX7	CD38_HUMAN	Decreases Expression	[28]
Ephrin type-B receptor 2 (EPHB2)	OT8VZ6C5	EPHB2_HUMAN	Decreases Expression	[28]
Flavin reductase (BLVRB)	OTHCFN2C	BLVRB_HUMAN	Increases Expression	[28]
G1/S-specific cyclin-D2 (CCND2)	OTDULQF9	CCND2_HUMAN	Decreases Expression	[28]
Homeobox protein Hox-A11 (HOXA11)	OT42C4HF	HXA11_HUMAN	Decreases Expression	[28]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Increases Expression	[28]
Stress-induced-phosphoprotein 1 (STIP1)	OT7TXLOX	STIP1_HUMAN	Decreases Expression	[28]
Guanylate-binding protein 2 (GBP2)	OTVU4G07	GBP2_HUMAN	Increases Expression	[28]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Expression	[28]
Protein phosphatase 1A (PPM1A)	OT1U770U	PPM1A_HUMAN	Increases Expression	[28]
Transcription factor 7 (TCF7)	OT1ID822	TCF7_HUMAN	Decreases Expression	[28]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2)	OTUE7Z91	MP2K2_HUMAN	Decreases Expression	[28]
Transgelin-2 (TAGLN2)	OTUXZGDQ	TAGL2_HUMAN	Decreases Expression	[28]
Pre-B-cell leukemia transcription factor 3 (PBX3)	OT8WMVM4	PBX3_HUMAN	Decreases Expression	[28]
Interleukin-15 (IL15)	OTQSYWQS	IL15_HUMAN	Increases Expression	[28]
Trifunctional enzyme subunit alpha, mitochondrial (HADHA)	OTO557N2	ECHA_HUMAN	Increases Expression	[28]
Eukaryotic translation initiation factor 2 subunit 3 (EIF2S3)	OTARRES9	IF2G_HUMAN	Decreases Expression	[28]
B-cell lymphoma 6 protein (BCL6)	OTQAWWO1	BCL6_HUMAN	Increases Expression	[28]
Lysine-specific demethylase 5C (KDM5C)	OTZ6E0HY	KDM5C_HUMAN	Decreases Expression	[28]
Eukaryotic translation initiation factor 1 (EIF1)	OTB4GZ0V	EIF1_HUMAN	Increases Expression	[28]
5-hydroxytryptamine receptor 2B (HTR2B)	OTM1AD9J	5HT2B_HUMAN	Decreases Expression	[28]
Lamina-associated polypeptide 2, isoform alpha (TMPO)	OTL68EL4	LAP2A_HUMAN	Decreases Expression	[28]
ETS translocation variant 4 (ETV4)	OT8C98UZ	ETV4_HUMAN	Decreases Expression	[28]
Killer cell immunoglobulin-like receptor 2DS4 (KIR2DS4)	OT00N6UJ	KI2S4_HUMAN	Decreases Expression	[28]
26S proteasome regulatory subunit 6B (PSMC4)	OTS3XN41	PRS6B_HUMAN	Increases Expression	[28]
Lys-63-specific deubiquitinase BRCC36 (BRCC3)	OTK0ZN7Y	BRCC3_HUMAN	Decreases Expression	[28]
LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1)	OT729S0T	LIMS1_HUMAN	Increases Expression	[28]
NADP-dependent malic enzyme (ME1)	OTSVEUQE	MAOX_HUMAN	Increases Expression	[28]
MAP kinase-activated protein kinase 2 (MAPKAPK2)	OT460SBO	MAPK2_HUMAN	Decreases Expression	[28]
Large ribosomal subunit protein bL19m (MRPL19)	OTRBKF6R	RM19_HUMAN	Increases Expression	[28]
Beta-arrestin-1 (ARRB1)	OT2NJS37	ARRB1_HUMAN	Decreases Expression	[28]
Ubiquitin-conjugating enzyme E2 R1 (CDC34)	OTNBK390	UB2R1_HUMAN	Increases Expression	[28]
Choline-phosphate cytidylyltransferase A (PCYT1A)	OTMH0YLN	PCY1A_HUMAN	Increases Expression	[28]
Protein phosphatase 1F (PPM1F)	OTU0MVR7	PPM1F_HUMAN	Increases Expression	[28]
Protein numb homolog (NUMB)	OTMB586Q	NUMB_HUMAN	Increases Expression	[28]
Presenilin-1 (PSEN1)	OTKL39RT	PSN1_HUMAN	Decreases Expression	[28]
Cytosolic purine 5'-nucleotidase (NT5C2)	OTJMF66Z	5NTC_HUMAN	Increases Expression	[28]
DNA ligase 4 (LIG4)	OT40DNXU	DNLI4_HUMAN	Increases Expression	[28]
Dynamin-2 (DNM2)	OTUYU2U3	DYN2_HUMAN	Decreases Expression	[28]
Poly(A) polymerase alpha (PAPOLA)	OTPHD65D	PAPOA_HUMAN	Decreases Expression	[28]
Tyrosine-protein kinase Blk (BLK)	OT1EB8MT	BLK_HUMAN	Decreases Expression	[28]
Succinate-semialdehyde dehydrogenase, mitochondrial (ALDH5A1)	OTF3TBTK	SSDH_HUMAN	Decreases Expression	[28]
26S proteasome non-ATPase regulatory subunit 7 (PSMD7)	OT7PZZ4K	PSMD7_HUMAN	Increases Expression	[28]
N-sulphoglucosamine sulphohydrolase (SGSH)	OTLSSEOS	SPHM_HUMAN	Increases Expression	[28]
AF4/FMR2 family member 1 (AFF1)	OTT2C78E	AFF1_HUMAN	Increases Expression	[28]
Importin subunit alpha-1 (KPNA2)	OTU7FOE6	IMA1_HUMAN	Increases Expression	[28]
Diacylglycerol kinase epsilon (DGKE)	OTWS86AS	DGKE_HUMAN	Decreases Expression	[28]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6)	OTK13JKC	MP2K6_HUMAN	Decreases Expression	[28]
Rho GDP-dissociation inhibitor 1 (ARHGDIA)	OTEXWJDO	GDIR1_HUMAN	Decreases Expression	[28]
Cysteine-rich protein 2 (CRIP2)	OTVVJSYX	CRIP2_HUMAN	Decreases Expression	[28]
Serine/threonine-protein phosphatase 5 (PPP5C)	OTC3HT6Y	PPP5_HUMAN	Decreases Expression	[28]
Delta-1-pyrroline-5-carboxylate synthase (ALDH18A1)	OT6W40XU	P5CS_HUMAN	Decreases Expression	[28]
Proteinase-activated receptor 2 (F2RL1)	OTMRMJ8N	PAR2_HUMAN	Decreases Expression	[28]
Myc-associated zinc finger protein (MAZ)	OTEHKN1M	MAZ_HUMAN	Decreases Expression	[28]
ADP-ribosylation factor-like protein 4C (ARL4C)	OTQ3QNNU	ARL4C_HUMAN	Decreases Expression	[28]
Small integral membrane protein 11 (SMIM11)	OTZPLVUC	SIM11_HUMAN	Decreases Expression	[28]
Triosephosphate isomerase (TPI1)	OT14KP4B	TPIS_HUMAN	Increases Expression	[28]
Cell division control protein 42 homolog (CDC42)	OT5QBC5M	CDC42_HUMAN	Decreases Expression	[28]
C-X-C chemokine receptor type 4 (CXCR4)	OTUFSBX2	CXCR4_HUMAN	Decreases Expression	[28]
Large ribosomal subunit protein uL24 (RPL26)	OTFNRC27	RL26_HUMAN	Increases Expression	[28]
cAMP-dependent protein kinase inhibitor alpha (PKIA)	OT8M5GVO	IPKA_HUMAN	Increases Expression	[28]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Decreases Expression	[28]
Small ribosomal subunit protein uS17 (RPS11)	OTILZE44	RS11_HUMAN	Increases Expression	[28]
ADP-ribosylation factor 6 (ARF6)	OTVV7KJO	ARF6_HUMAN	Increases Expression	[28]
Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP1A)	OT6285L4	FKB1A_HUMAN	Decreases Expression	[28]
Calcineurin subunit B type 1 (PPP3R1)	OTGQNFJQ	CANB1_HUMAN	Decreases Expression	[28]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A)	OT9297OG	2ABA_HUMAN	Increases Expression	[28]
Small ubiquitin-related modifier 1 (SUMO1)	OTJFD4P5	SUMO1_HUMAN	Increases Expression	[28]
Eukaryotic translation initiation factor 5A-1 (EIF5A)	OTQ8DJX5	IF5A1_HUMAN	Decreases Expression	[28]
DNA-dependent protein kinase catalytic subunit (PRKDC)	OTJVS4EG	PRKDC_HUMAN	Decreases Expression	[28]
Small ribosomal subunit protein uS5m (MRPS5)	OTZZR208	RT05_HUMAN	Decreases Expression	[28]
Spectrin beta chain, non-erythrocytic 1 (SPTBN1)	OTOVM4D4	SPTB2_HUMAN	Increases Expression	[28]
Large neutral amino acids transporter small subunit 1 (SLC7A5)	OT2WPVXD	LAT1_HUMAN	Decreases Expression	[28]
2-oxoglutarate dehydrogenase complex component E1 (OGDH)	OTHGTQWF	ODO1_HUMAN	Decreases Expression	[28]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1)	OT8LCZCT	MMSA_HUMAN	Decreases Expression	[28]
Mitochondrial 2-oxoglutarate/malate carrier protein (SLC25A11)	OT7EVFBK	M2OM_HUMAN	Decreases Expression	[28]
Glutathione S-transferase Mu 4 (GSTM4)	OTOTF8DU	GSTM4_HUMAN	Decreases Expression	[28]
cAMP-responsive element modulator (CREM)	OTJIJ5AL	CREM_HUMAN	Increases Expression	[28]
Centromere protein C (CENPC)	OTVJ6VE9	CENPC_HUMAN	Increases Expression	[28]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[28]
Neurogenic locus notch homolog protein 2 (NOTCH2)	OTQ3Y9PA	NOTC2_HUMAN	Decreases Expression	[28]
CTD small phosphatase-like protein 2 (CTDSPL2)	OTPF8W4P	CTSL2_HUMAN	Decreases Expression	[28]
Tyrosine-protein phosphatase non-receptor type 11 (PTPN11)	OTFH9M73	PTN11_HUMAN	Decreases Expression	[28]
Early activation antigen CD69 (CD69)	OTGJHSVP	CD69_HUMAN	Increases Expression	[28]
Serine/arginine-rich splicing factor 1 (SRSF1)	OTF61HOV	SRSF1_HUMAN	Decreases Expression	[28]
Rho GTPase-activating protein 1 (ARHGAP1)	OT0H2ZBZ	RHG01_HUMAN	Decreases Expression	[28]
FACT complex subunit SSRP1 (SSRP1)	OT5TYJK9	SSRP1_HUMAN	Decreases Expression	[28]
Sodium/bile acid cotransporter 7 (SLC10A7)	OTYLAWNV	NTCP7_HUMAN	Increases Expression	[28]
Apolipoprotein B receptor (APOBR)	OT9EUZX3	APOBR_HUMAN	Decreases Expression	[28]
Nuclear factor 1 A-type (NFIA)	OTDHQ9CG	NFIA_HUMAN	Decreases Expression	[28]
Interferon-related developmental regulator 2 (IFRD2)	OT2URF18	IFRD2_HUMAN	Decreases Expression	[28]
Protein AF1q (MLLT11)	OTG5RVHC	AF1Q_HUMAN	Increases Expression	[28]
PR domain zinc finger protein 2 (PRDM2)	OT8L7CGX	PRDM2_HUMAN	Decreases Expression	[28]
Dual specificity protein phosphatase 4 (DUSP4)	OT6WAO12	DUS4_HUMAN	Decreases Expression	[28]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Decreases Expression	[28]
Chromobox protein homolog 3 (CBX3)	OTOP9RLD	CBX3_HUMAN	Increases Expression	[28]
Phosducin-like protein (PDCL)	OTDNHIXG	PHLP_HUMAN	Increases Expression	[28]
DNA-binding protein Ikaros (IKZF1)	OTCW1FKL	IKZF1_HUMAN	Decreases Expression	[28]
Protein OS-9 (OS9)	OTB5B2TY	OS9_HUMAN	Increases Expression	[28]
Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5)	OT404F9K	FKBP5_HUMAN	Decreases Expression	[28]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Increases Expression	[28]
Transformer-2 protein homolog alpha (TRA2A)	OT5NHOO3	TRA2A_HUMAN	Decreases Expression	[28]
Rap guanine nucleotide exchange factor 1 (RAPGEF1)	OTZ0TBN1	RPGF1_HUMAN	Decreases Expression	[28]
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A (PDE7A)	OTVDV4IT	PDE7A_HUMAN	Decreases Expression	[28]
Nuclear transcription factor Y subunit gamma (NFYC)	OTZVVEV7	NFYC_HUMAN	Decreases Expression	[28]
Transcription factor Dp-1 (TFDP1)	OT6RZ7VT	TFDP1_HUMAN	Decreases Expression	[28]
Fas-activated serine/threonine kinase (FASTK)	OTTHFZMP	FASTK_HUMAN	Decreases Expression	[28]
Mediator of DNA damage checkpoint protein 1 (MDC1)	OTEUQH4J	MDC1_HUMAN	Decreases Expression	[28]
Structural maintenance of chromosomes protein 1A (SMC1A)	OT9ZMRK9	SMC1A_HUMAN	Decreases Expression	[28]
Neutral alpha-glucosidase AB (GANAB)	OTYLXY4M	GANAB_HUMAN	Decreases Expression	[28]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform (PPP2R5D)	OT43TTX0	2A5D_HUMAN	Decreases Expression	[28]
Kinesin-like protein KIF22 (KIF22)	OTY6X6BL	KIF22_HUMAN	Decreases Expression	[28]
Killer cell immunoglobulin-like receptor 3DS1 (KIR3DS1)	OTJWIO4T	KI3S1_HUMAN	Decreases Expression	[28]
Killer cell immunoglobulin-like receptor 2DS3 (KIR2DS3)	OT3PSLDL	KI2S3_HUMAN	Decreases Expression	[28]
DAZ-associated protein 2 (DAZAP2)	OTNURO9F	DAZP2_HUMAN	Decreases Expression	[28]
Neutrophil cytosol factor 4 (NCF4)	OTX007YL	NCF4_HUMAN	Decreases Expression	[28]
kinase isozyme 2, mitochondrial (PDK2)	OTM436F9	PDK2_HUMAN	Decreases Expression	[28]
Leucine-rich repeat-containing protein 41 (LRRC41)	OT4YSBV5	LRC41_HUMAN	Decreases Expression	[28]
Ras suppressor protein 1 (RSU1)	OTO5GHT1	RSU1_HUMAN	Increases Expression	[28]
Scaffold attachment factor B1 (SAFB)	OTGRV2LW	SAFB1_HUMAN	Decreases Expression	[28]
NF-kappa-B inhibitor beta (NFKBIB)	OTY1ZJXH	IKBB_HUMAN	Increases Expression	[28]
NGFI-A-binding protein 2 (NAB2)	OTG4BDF3	NAB2_HUMAN	Decreases Expression	[28]
Neuronal pentraxin-1 (NPTX1)	OTKVHCV0	NPTX1_HUMAN	Decreases Expression	[28]
Coiled-coil domain-containing protein 6 (CCDC6)	OTXRQDYG	CCDC6_HUMAN	Decreases Expression	[28]
Drebrin (DBN1)	OTZVKG8A	DREB_HUMAN	Increases Expression	[28]
Solute carrier family 35 member G1 (SLC35G1)	OTKZUA8O	S35G1_HUMAN	Decreases Expression	[28]
Protein mono-ADP-ribosyltransferase PARP6 (PARP6)	OTWSXW4O	PARP6_HUMAN	Decreases Expression	[28]
Leucine-rich repeat flightless-interacting protein 1 (LRRFIP1)	OTN7XAUD	LRRF1_HUMAN	Increases Expression	[28]
Polycomb group RING finger protein 3 (PCGF3)	OTY7TPPZ	PCGF3_HUMAN	Increases Expression	[28]
NAD kinase 2, mitochondrial (NADK2)	OT1I8GDE	NAKD2_HUMAN	Increases Expression	[28]
B-cell CLL/lymphoma 7 protein family member A (BCL7A)	OTYFUJTP	BCL7A_HUMAN	Decreases Expression	[28]
Glycerol-3-phosphate acyltransferase 3 (GPAT3)	OTJUGPK0	GPAT3_HUMAN	Increases Expression	[28]
Acylglycerol kinase, mitochondrial (AGK)	OTJGWBYT	AGK_HUMAN	Decreases Expression	[28]
Vesicle transport protein SFT2C (SFT2D3)	OT0IEAAR	SFT2C_HUMAN	Decreases Expression	[28]
Transmembrane protein 41B (TMEM41B)	OTW0B0KS	TM41B_HUMAN	Increases Expression	[28]
Torsin-1A-interacting protein 1 (TOR1AIP1)	OTTG8MAK	TOIP1_HUMAN	Decreases Expression	[28]
Tetratricopeptide repeat protein 39A (TTC39A)	OT80PQWX	TT39A_HUMAN	Increases Expression	[28]
Protein furry homolog (FRY)	OT74IAG2	FRY_HUMAN	Increases Expression	[28]
Probable E3 ubiquitin-protein ligase HECTD2 (HECTD2)	OTDIBGQV	HECD2_HUMAN	Increases Expression	[28]
G-protein coupled receptor 157 (GPR157)	OTE7K9D7	GP157_HUMAN	Decreases Expression	[28]
Obscurin (OBSCN)	OTT14OVX	OBSCN_HUMAN	Decreases Expression	[28]
G kinase-anchoring protein 1 (GKAP1)	OTHZRJ56	GKAP1_HUMAN	Increases Expression	[28]
Protein TASOR 2 (TASOR2)	OTN4VE8H	TASO2_HUMAN	Decreases Expression	[28]
Sushi domain-containing protein 4 (SUSD4)	OTWCJTT3	SUSD4_HUMAN	Decreases Expression	[28]
Proteasome adapter and scaffold protein ECM29 (ECPAS)	OT1C0KOI	ECM29_HUMAN	Increases Expression	[28]
DENN domain-containing protein 4C (DENND4C)	OT8SYN47	DEN4C_HUMAN	Increases Expression	[28]
Pecanex-like protein 4 (PCNX4)	OTV474RQ	PCX4_HUMAN	Increases Expression	[28]
Protein SPT2 homolog (SPTY2D1)	OT1RY99Z	SPT2_HUMAN	Increases Expression	[28]
CWF19-like protein 1 (CWF19L1)	OTAMYTOW	C19L1_HUMAN	Decreases Expression	[28]
U11/U12 small nuclear ribonucleoprotein 48 kDa protein (SNRNP48)	OTSR6DEJ	SNR48_HUMAN	Increases Expression	[28]
Tyrosine-protein kinase STYK1 (STYK1)	OT61CSU7	STYK1_HUMAN	Increases Expression	[28]
SPRY domain-containing SOCS box protein 3 (SPSB3)	OTHGEE2K	SPSB3_HUMAN	Increases Expression	[28]
E3 ubiquitin-protein ligase TRIM65 (TRIM65)	OTSQTK3A	TRI65_HUMAN	Decreases Expression	[28]
Leucine-rich repeat and fibronectin type-III domain-containing protein 4 (LRFN4)	OT7RWBKE	LRFN4_HUMAN	Decreases Expression	[28]
Type-1 angiotensin II receptor-associated protein (AGTRAP)	OT02N7LD	ATRAP_HUMAN	Decreases Expression	[28]
Transmembrane protein 92 (TMEM92)	OTTKJ2C0	TMM92_HUMAN	Decreases Expression	[28]
MICOS complex subunit MIC27 (APOOL)	OTC1WT8O	MIC27_HUMAN	Increases Expression	[28]
DnaJ homolog subfamily C member 14 (DNAJC14)	OT7DPIVN	DJC14_HUMAN	Decreases Expression	[28]
TBC1 domain family member 9 (TBC1D9)	OTSSCTB5	TBCD9_HUMAN	Increases Expression	[28]
Ras-associated and pleckstrin homology domains-containing protein 1 (RAPH1)	OTMQXW7S	RAPH1_HUMAN	Increases Expression	[28]
Serine/threonine-protein kinase MARK2 (MARK2)	OTJWGLUZ	MARK2_HUMAN	Decreases Expression	[28]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)	OTE8GBUR	RIR2B_HUMAN	Increases Expression	[28]
Probable C-mannosyltransferase DPY19L4 (DPY19L4)	OTQ89TXA	D19L4_HUMAN	Increases Expression	[28]
Coiled-coil domain-containing protein 186 (CCDC186)	OTONSQAD	CC186_HUMAN	Increases Expression	[28]
C-myc promoter-binding protein (DENND4A)	OT8FFZ29	MYCPP_HUMAN	Increases Expression	[28]
Cytochrome P450 2U1 (CYP2U1)	OT6RXLXS	CP2U1_HUMAN	Increases Expression	[28]
HAUS augmin-like complex subunit 6 (HAUS6)	OT7ZVR57	HAUS6_HUMAN	Increases Expression	[28]
Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase (PIP4P1)	OT991XS0	PP4P1_HUMAN	Decreases Expression	[28]
Kinectin (KTN1)	OTQAV541	KTN1_HUMAN	Increases Expression	[28]
Phosphatidylcholine:ceramide cholinephosphotransferase 1 (SGMS1)	OTZQE7PW	SMS1_HUMAN	Increases Expression	[28]
Sodium-independent sulfate anion transporter (SLC26A11)	OTWBV9CR	S2611_HUMAN	Increases Expression	[28]
RNA-binding protein MEX3D (MEX3D)	OTAUWRK7	MEX3D_HUMAN	Decreases Expression	[28]
Dynein axonemal assembly factor 5 (DNAAF5)	OTN0CT52	DAAF5_HUMAN	Decreases Expression	[28]
Syntaxin-12 (STX12)	OT5IBQ62	STX12_HUMAN	Increases Expression	[28]
Mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3)	OTNJX38T	M4K3_HUMAN	Increases Expression	[28]
Protein FAM219A (FAM219A)	OTAFZHY9	F219A_HUMAN	Increases Expression	[28]
Mitofusin-1 (MFN1)	OTCBXQZF	MFN1_HUMAN	Decreases Expression	[28]
Pleckstrin homology domain-containing family M member 2 (PLEKHM2)	OT4ZYV73	PKHM2_HUMAN	Decreases Expression	[28]
Mitochondrial Rho GTPase 2 (RHOT2)	OTV8WT2L	MIRO2_HUMAN	Decreases Expression	[28]
Xaa-Arg dipeptidase (PM20D2)	OTD2Y7LU	P20D2_HUMAN	Increases Expression	[28]
Solute carrier family 38 member 6 (SLC38A6)	OTIC8SHQ	S38A6_HUMAN	Increases Expression	[28]
Abl interactor 1 (ABI1)	OT5H4M62	ABI1_HUMAN	Increases Expression	[28]
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (GCNT2)	OTRUIMC4	GNT2A_HUMAN	Increases Expression	[28]
Protein FAM43A (FAM43A)	OT5RPQRE	FA43A_HUMAN	Decreases Expression	[28]
CAP-Gly domain-containing linker protein 4 (CLIP4)	OT75KVQK	CLIP4_HUMAN	Increases Expression	[28]
Putative transporter SVOPL (SVOPL)	OTJ4G2ND	SVOPL_HUMAN	Decreases Expression	[28]
Polypeptide N-acetylgalactosaminyltransferase 4 (GALNT4)	OT6WKC13	GALT4_HUMAN	Increases Expression	[28]
Coiled-coil domain-containing protein 82 (CCDC82)	OT16EAZ7	CCD82_HUMAN	Increases Expression	[28]
SH2 domain-containing protein 3C (SH2D3C)	OTAGXO0N	SH2D3_HUMAN	Decreases Expression	[28]
Methyltransferase-like protein 27 (METTL27)	OTOF0GTU	MET27_HUMAN	Decreases Expression	[28]
ADP-ribosylation factor GTPase-activating protein 1 (ARFGAP1)	OTM3KHIE	ARFG1_HUMAN	Decreases Expression	[28]
Protein KRI1 homolog (KRI1)	OT1IGOK7	KRI1_HUMAN	Increases Expression	[28]
ATPase family gene 2 protein homolog A (AFG2A)	OTPZKWN7	AFG2A_HUMAN	Increases Expression	[28]
Equilibrative nucleobase transporter 1 (SLC43A3)	OTR60ZLA	S43A3_HUMAN	Decreases Expression	[28]
Retinol dehydrogenase 13 (RDH13)	OT48VJ65	RDH13_HUMAN	Increases Expression	[28]
Neuropilin and tolloid-like protein 2 (NETO2)	OT0YAMC0	NETO2_HUMAN	Decreases Expression	[28]
Polyhomeotic-like protein 3 (PHC3)	OTTTLIAP	PHC3_HUMAN	Increases Expression	[28]
Glutathione S-transferase C-terminal domain-containing protein (GSTCD)	OTIIINMT	GSTCD_HUMAN	Decreases Expression	[28]
Folliculin (FLCN)	OTVM78XM	FLCN_HUMAN	Increases Expression	[28]
Tubulin--tyrosine ligase (TTL)	OTSS1CK4	TTL_HUMAN	Decreases Expression	[28]
Protein NEDD1 (NEDD1)	OTBD6X77	NEDD1_HUMAN	Increases Expression	[28]
Protein FAM76A (FAM76A)	OT28WHO4	FA76A_HUMAN	Increases Expression	[28]
Proline-rich protein 7 (PRR7)	OT56XAQK	PRR7_HUMAN	Decreases Expression	[28]
Transmembrane protein 254 (TMEM254)	OTGDPU8S	TM254_HUMAN	Decreases Expression	[28]
Retinol dehydrogenase 11 (RDH11)	OTIND43N	RDH11_HUMAN	Increases Expression	[28]
POC1 centriolar protein homolog B (POC1B)	OTDIMIRZ	POC1B_HUMAN	Increases Expression	[28]
Interferon-induced protein 44 (IFI44)	OTOKSZVA	IFI44_HUMAN	Increases Expression	[28]
Large ribosomal subunit protein uL30m (MRPL30)	OT26OPYV	RM30_HUMAN	Decreases Expression	[28]
RB1-inducible coiled-coil protein 1 (RB1CC1)	OTZK8PFX	RBCC1_HUMAN	Increases Expression	[28]
Elongator complex protein 5 (ELP5)	OTW5R7YD	ELP5_HUMAN	Decreases Expression	[28]
DDB1- and CUL4-associated factor 11 (DCAF11)	OTNSGYK1	DCA11_HUMAN	Decreases Expression	[28]
Arginine/serine-rich protein PNISR (PNISR)	OTUM02FW	PNISR_HUMAN	Increases Expression	[28]
General transcription factor 3C polypeptide 2 (GTF3C2)	OTWDANLJ	TF3C2_HUMAN	Decreases Expression	[28]
Transmembrane protein 263 (TMEM263)	OTO1RSTS	TM263_HUMAN	Increases Expression	[28]
Protein THEM6 (THEM6)	OT51SVLH	THEM6_HUMAN	Decreases Expression	[28]
Pleckstrin homology-like domain family A member 1 (PHLDA1)	OTFTWMIQ	PHLA1_HUMAN	Increases Expression	[28]
Hexosaminidase D (HEXD)	OTTMQKLM	HEXD_HUMAN	Decreases Expression	[28]
E3 ubiquitin-protein ligase RNF138 (RNF138)	OTPU0CO4	RN138_HUMAN	Increases Expression	[28]
Heterogeneous nuclear ribonucleoprotein L-like (HNRNPLL)	OTA6Q5E0	HNRLL_HUMAN	Increases Expression	[28]
Uncharacterized protein C4orf3 (C4ORF3)	OT6TFN1O	CD003_HUMAN	Decreases Expression	[28]
tRNA-splicing endonuclease subunit Sen15 (TSEN15)	OT14UW31	SEN15_HUMAN	Decreases Expression	[28]
Palladin (PALLD)	OTZ2MUJZ	PALLD_HUMAN	Increases Expression	[28]
Protein N-lysine methyltransferase METTL21A (METTL21A)	OTXJTNXY	MT21A_HUMAN	Increases Expression	[28]
Histone acetyltransferase KAT6B (KAT6B)	OTMUDTAH	KAT6B_HUMAN	Decreases Expression	[28]
E3 ubiquitin-protein ligase rififylin (RFFL)	OT85MGDH	RFFL_HUMAN	Increases Expression	[28]
Aquaporin-3 (AQP3)	OT2J7JPD	AQP3_HUMAN	Increases Expression	[28]
Proteasome inhibitor PI31 subunit (PSMF1)	OTX84WLQ	PSMF1_HUMAN	Decreases Expression	[28]
Protein FAM168A (FAM168A)	OTDXQCS5	F168A_HUMAN	Increases Expression	[28]
Protein NDRG1 (NDRG1)	OTVO66BO	NDRG1_HUMAN	Increases Expression	[28]
TRAF family member-associated NF-kappa-B activator (TANK)	OTZSGFIK	TANK_HUMAN	Increases Expression	[28]
Ras-related protein Rab-8B (RAB8B)	OTBPUHV9	RAB8B_HUMAN	Decreases Expression	[28]
GTP-binding protein Rit1 (RIT1)	OTVNOGOH	RIT1_HUMAN	Increases Expression	[28]
Phosphorylase b kinase regulatory subunit beta (PHKB)	OTKXZZIU	KPBB_HUMAN	Increases Expression	[28]
BLOC-2 complex member HPS3 (HPS3)	OTAKROK7	HPS3_HUMAN	Decreases Expression	[28]
F-box/WD repeat-containing protein 7 (FBXW7)	OTJXE4OT	FBXW7_HUMAN	Decreases Expression	[28]
Polyamine deacetylase HDAC10 (HDAC10)	OTHCKKUQ	HDA10_HUMAN	Decreases Expression	[28]
NXPE family member 3 (NXPE3)	OTLVZ8W2	NXPE3_HUMAN	Increases Expression	[28]
Transmembrane protein 230 (TMEM230)	OTAFALFV	TM230_HUMAN	Decreases Expression	[28]
SOSS complex subunit B2 (NABP1)	OTFTNFHW	SOSB2_HUMAN	Increases Expression	[28]
Ankyrin repeat domain-containing protein 9 (ANKRD9)	OT7VGO6G	ANKR9_HUMAN	Increases Expression	[28]
ADP-ribosylation factor-like protein 8A (ARL8A)	OTEYM6FA	ARL8A_HUMAN	Increases Expression	[28]
m7GpppX diphosphatase (DCPS)	OT1FZVC9	DCPS_HUMAN	Decreases Expression	[28]
Protein FAM241B (FAM241B)	OTLISLRC	F241B_HUMAN	Increases Expression	[28]
R3H domain-containing protein 4 (R3HDM4)	OTE0Q78Q	R3HD4_HUMAN	Decreases Expression	[28]
E3 ubiquitin-protein ligase CHFR (CHFR)	OTRAD2TT	CHFR_HUMAN	Decreases Expression	[28]
ATP-dependent DNA helicase DDX11 (DDX11)	OT1WR3MD	DDX11_HUMAN	Decreases Expression	[28]
Kelch domain-containing protein 7B (KLHDC7B)	OT2H5BNX	KLD7B_HUMAN	Increases Expression	[28]
H/ACA ribonucleoprotein complex non-core subunit NAF1 (NAF1)	OTMJKJAK	NAF1_HUMAN	Increases Expression	[28]
Histone-lysine N-methyltransferase EHMT2 (EHMT2)	OTC4DWB6	EHMT2_HUMAN	Decreases Expression	[28]
Uncharacterized protein C9orf85 (C9ORF85)	OTJWBPL3	CI085_HUMAN	Increases Expression	[28]
Pannexin-2 (PANX2)	OTAQ2S8R	PANX2_HUMAN	Increases Expression	[28]
Ribosomal protein S6 kinase delta-1 (RPS6KC1)	OT2LRTG4	KS6C1_HUMAN	Increases Expression	[28]
Structural maintenance of chromosomes protein 6 (SMC6)	OT3IBHQD	SMC6_HUMAN	Increases Expression	[28]
Protein orai-2 (ORAI2)	OTYISRYH	ORAI2_HUMAN	Decreases Expression	[28]
E3 ubiquitin-protein ligase RING2 (RNF2)	OTFPLOIN	RING2_HUMAN	Increases Expression	[28]
Krueppel-like factor 6 (KLF6)	OTQY9S7F	KLF6_HUMAN	Increases Expression	[28]
Succinate dehydrogenase cytochrome b560 subunit, mitochondrial (SDHC)	OTC8G2MX	C560_HUMAN	Decreases Expression	[28]
Sigma non-opioid intracellular receptor 1 (SIGMAR1)	OTDORW5C	SGMR1_HUMAN	Decreases Expression	[28]
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha (PIP5K1A)	OTVTB5R5	PI51A_HUMAN	Decreases Expression	[28]
Apolipoprotein L4 (APOL4)	OTTOH86V	APOL4_HUMAN	Decreases Expression	[28]
Protein NipSnap homolog 1 (NIPSNAP1)	OTKXKUT8	NIPS1_HUMAN	Decreases Expression	[28]
Protein FAM118B (FAM118B)	OTRLY4B0	F118B_HUMAN	Increases Expression	[28]
Target of rapamycin complex 2 subunit MAPKAP1 (MAPKAP1)	OTYKB9G3	SIN1_HUMAN	Decreases Expression	[28]
TM2 domain-containing protein 3 (TM2D3)	OT6MS96W	TM2D3_HUMAN	Increases Expression	[28]
Ferroptosis suppressor protein 1 (AIFM2)	OT57XWXO	FSP1_HUMAN	Increases Expression	[28]
Tubulin-specific chaperone D (TBCD)	OTS4JKNQ	TBCD_HUMAN	Decreases Expression	[28]
Iron-sulfur cluster assembly 1 homolog, mitochondrial (ISCA1)	OTU230MC	ISCA1_HUMAN	Increases Expression	[28]
Bublin coiled-coil protein (BBLN)	OTUMVEWE	BBLN_HUMAN	Decreases Expression	[28]
Coiled-coil domain-containing protein 32 (CCDC32)	OTPPUFIF	CCD32_HUMAN	Increases Expression	[28]
Kinesin-like protein KIFC1 (KIFC1)	OTNQDS00	KIFC1_HUMAN	Decreases Expression	[28]
Katanin p60 ATPase-containing subunit A-like 1 (KATNAL1)	OTBUZ7KA	KATL1_HUMAN	Increases Expression	[28]
Protein C1orf43 (C1ORF43)	OTT9CVZR	CA043_HUMAN	Decreases Expression	[28]
TM2 domain-containing protein 2 (TM2D2)	OTB51WEY	TM2D2_HUMAN	Increases Expression	[28]
Sphingosine-1-phosphate phosphatase 1 (SGPP1)	OT9X54CQ	SGPP1_HUMAN	Increases Expression	[28]
FSD1-like protein (FSD1L)	OTBQ48RF	FSD1L_HUMAN	Increases Expression	[28]
C-type lectin domain family 7 member A (CLEC7A)	OTRTBH27	CLC7A_HUMAN	Increases Expression	[28]
Serrate RNA effector molecule homolog (SRRT)	OTMYPSWV	SRRT_HUMAN	Decreases Expression	[28]
Protein kinase C and casein kinase substrate in neurons protein 1 (PACSIN1)	OT07Z2RQ	PACN1_HUMAN	Increases Expression	[28]
Sterile alpha motif domain-containing protein 10 (SAMD10)	OTBKWB5C	SAM10_HUMAN	Decreases Expression	[28]
ATP-binding cassette sub-family A member 2 (ABCA2)	OTVSYK0X	ABCA2_HUMAN	Decreases Expression	[28]
INO80 complex subunit B (INO80B)	OTSHV8JF	IN80B_HUMAN	Decreases Expression	[28]
Uncharacterized protein C6orf62 (C6ORF62)	OTGK4G35	CF062_HUMAN	Increases Expression	[28]
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1)	OT4U7SBG	GBRL1_HUMAN	Increases Expression	[28]
Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 (NUCKS1)	OTL4VJC5	NUCKS_HUMAN	Decreases Expression	[28]
Oxysterol-binding protein-related protein 2 (OSBPL2)	OTCK671N	OSBL2_HUMAN	Increases Expression	[28]
Dual specificity protein phosphatase 15 (DUSP15)	OTS6PQYL	DUS15_HUMAN	Decreases Expression	[28]
BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 3 (KCTD10)	OT5HFZXU	BACD3_HUMAN	Increases Expression	[28]
UPF0696 protein C11orf68 (C11ORF68)	OTOKOGZ6	CK068_HUMAN	Decreases Expression	[28]
Differentially expressed in FDCP 6 homolog (DEF6)	OTIRBYVK	DEFI6_HUMAN	Decreases Expression	[28]
Sentrin-specific protease 3 (SENP3)	OTFQDOMC	SENP3_HUMAN	Decreases Expression	[28]
ESF1 homolog (ESF1)	OTHEDM0A	ESF1_HUMAN	Increases Expression	[28]
RNA polymerase II-associated protein 3 (RPAP3)	OTCW17LF	RPAP3_HUMAN	Increases Expression	[28]
Sin3 histone deacetylase corepressor complex component SDS3 (SUDS3)	OTZ1AARI	SDS3_HUMAN	Increases Expression	[28]
Caspase activity and apoptosis inhibitor 1 (CAAP1)	OTD2DN1Z	CAAP1_HUMAN	Increases Expression	[28]
Kinesin-like protein KIF9 (KIF9)	OT7W6VI1	KIF9_HUMAN	Decreases Expression	[28]
E3 ubiquitin-protein ligase SMURF2 (SMURF2)	OT3TRVL7	SMUF2_HUMAN	Increases Expression	[28]
Transcription factor IIIB 50 kDa subunit (BRF2)	OT2C6TH2	BRF2_HUMAN	Increases Expression	[28]
Retinoid-inducible serine carboxypeptidase (SCPEP1)	OT43LYEZ	RISC_HUMAN	Increases Expression	[28]
POZ-, AT hook-, and zinc finger-containing protein 1 (PATZ1)	OT0X9WGR	PATZ1_HUMAN	Decreases Expression	[28]
DNA dC->dU-editing enzyme APOBEC-3G (APOBEC3G)	OT410VP5	ABC3G_HUMAN	Increases Expression	[28]
DnaJ homolog subfamily C member 4 (DNAJC4)	OT4BUBQU	DNJC4_HUMAN	Decreases Expression	[28]
DNA-directed DNA/RNA polymerase mu (POLM)	OT0SRIP4	DPOLM_HUMAN	Decreases Expression	[28]
Carbohydrate sulfotransferase 11 (CHST11)	OTNJJ5Q1	CHSTB_HUMAN	Decreases Expression	[28]
Uncharacterized protein C14orf132 (C14ORF132)	OTBVC3AO	CN132_HUMAN	Decreases Expression	[28]
Putative RNA-binding protein Luc7-like 1 (LUC7L)	OT77JDB7	LUC7L_HUMAN	Increases Expression	[28]
Prefoldin subunit 4 (PFDN4)	OT5NRHER	PFD4_HUMAN	Increases Expression	[28]
Solute carrier family 35 member C2 (SLC35C2)	OT9H15XZ	S35C2_HUMAN	Decreases Expression	[28]
Gephyrin (GPHN)	OTAKK1SV	GEPH_HUMAN	Decreases Expression	[28]
Endophilin-B2 (SH3GLB2)	OTF7BB9S	SHLB2_HUMAN	Decreases Expression	[28]
Muscleblind-like protein 1 (MBNL1)	OTOV7J85	MBNL1_HUMAN	Decreases Expression	[28]
CDC42 small effector protein 2 (CDC42SE2)	OT8SG9I1	C42S2_HUMAN	Decreases Expression	[28]
RNA-binding protein PNO1 (PNO1)	OT010GIS	PNO1_HUMAN	Increases Expression	[28]
DDB1- and CUL4-associated factor 13 (DCAF13)	OTQQ0QXT	DCA13_HUMAN	Increases Expression	[28]
FGFR1 oncogene partner 2 (FGFR1OP2)	OTAHO1ZC	FGOP2_HUMAN	Increases Expression	[28]
DNA-directed RNA polymerase III subunit RPC5 (POLR3E)	OT69PWBM	RPC5_HUMAN	Increases Expression	[28]
Anoctamin-10 (ANO10)	OTG3BNOU	ANO10_HUMAN	Increases Expression	[28]
BSD domain-containing protein 1 (BSDC1)	OT853CP9	BSDC1_HUMAN	Increases Expression	[28]
G patch domain-containing protein 2-like (GPATCH2L)	OTETUZ64	GPT2L_HUMAN	Increases Expression	[28]
Ceroid-lipofuscinosis neuronal protein 6 (CLN6)	OT91IAYT	CLN6_HUMAN	Decreases Expression	[28]
AFG2-interacting ribosome maturation factor (AIRIM)	OTGG814L	AIRIM_HUMAN	Increases Expression	[28]
N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2)	OTE69HV8	B3GN2_HUMAN	Decreases Expression	[28]
Opioid growth factor receptor (OGFR)	OTROS6RJ	OGFR_HUMAN	Decreases Expression	[28]
E3 ubiquitin-protein ligase KCMF1 (KCMF1)	OTVTKFAU	KCMF1_HUMAN	Increases Expression	[28]
Stromal interaction molecule 2 (STIM2)	OTYNXAW0	STIM2_HUMAN	Decreases Expression	[28]
Inhibitor of Bruton tyrosine kinase (IBTK)	OTB2GM4G	IBTK_HUMAN	Increases Expression	[28]
Phosphatidylinositol 4-kinase beta (PI4KB)	OTI9UQSU	PI4KB_HUMAN	Decreases Expression	[28]
E3 ubiquitin-protein ligase RNF14 (RNF14)	OTWX0D0H	RNF14_HUMAN	Increases Expression	[28]
Fibulin-5 (FBLN5)	OTLVNZ8U	FBLN5_HUMAN	Decreases Expression	[28]
Beta-1,4-galactosyltransferase 6 (B4GALT6)	OTBM8F2U	B4GT6_HUMAN	Increases Expression	[28]
LIM domain-containing protein 1 (LIMD1)	OTN1CG6R	LIMD1_HUMAN	Increases Expression	[28]
Protein NDRG3 (NDRG3)	OTJTJCHD	NDRG3_HUMAN	Decreases Expression	[28]
LIM domain and actin-binding protein 1 (LIMA1)	OTONPC9R	LIMA1_HUMAN	Increases Expression	[28]
AF4/FMR2 family member 4 (AFF4)	OTTL5Y8R	AFF4_HUMAN	Increases Expression	[28]
NADH-cytochrome b5 reductase 1 (CYB5R1)	OTMDHMLA	NB5R1_HUMAN	Increases Expression	[28]
Methyl-CpG-binding domain protein 1 (MBD1)	OTD19VO6	MBD1_HUMAN	Decreases Expression	[28]
Oxidative stress-induced growth inhibitor 1 (OSGIN1)	OT9KIVZW	OSGI1_HUMAN	Increases Expression	[28]
Cell division cycle protein 23 homolog (CDC23)	OTC4O83E	CDC23_HUMAN	Increases Expression	[28]
Anaphase-promoting complex subunit 5 (ANAPC5)	OTGTJNNR	APC5_HUMAN	Decreases Expression	[28]
Calcipressin-3 (RCAN3)	OTTS3CQA	RCAN3_HUMAN	Decreases Expression	[28]
Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 (ASAP1)	OT4DLRYY	ASAP1_HUMAN	Decreases Expression	[28]
Tetratricopeptide repeat protein 7A (TTC7A)	OTDHLPQM	TTC7A_HUMAN	Decreases Expression	[28]
Nucleosome assembly protein 1-like 2 (NAP1L2)	OT8QI4GF	NP1L2_HUMAN	Increases Expression	[28]
Protein PHTF1 (PHTF1)	OTYCZ84A	PHTF1_HUMAN	Increases Expression	[28]
26S proteasome non-ATPase regulatory subunit 13 (PSMD13)	OTNQ351N	PSD13_HUMAN	Increases Expression	[28]
Cytosolic carboxypeptidase 1 (AGTPBP1)	OTR92JFR	CBPC1_HUMAN	Increases Expression	[28]
Serine/threonine-protein kinase ICK (CILK1)	OTWOYEYP	CILK1_HUMAN	Increases Expression	[28]
Structural maintenance of chromosomes protein 3 (SMC3)	OTWGFRHD	SMC3_HUMAN	Increases Expression	[28]
Myotubularin-related protein 6 (MTMR6)	OTQPAWI3	MTMR6_HUMAN	Increases Expression	[28]
Phospholipase A-2-activating protein (PLAA)	OTZ7NJGA	PLAP_HUMAN	Increases Expression	[28]
Phenylalanine--tRNA ligase alpha subunit (FARSA)	OT3U1P20	SYFA_HUMAN	Decreases Expression	[28]
Nck-associated protein 1 (NCKAP1)	OTEZQXXJ	NCKP1_HUMAN	Increases Expression	[28]
Kelch-like protein 20 (KLHL20)	OTC0SFS9	KLH20_HUMAN	Increases Expression	[28]
ARF GTPase-activating protein GIT1 (GIT1)	OTHO92S5	GIT1_HUMAN	Decreases Expression	[28]
RING finger protein 11 (RNF11)	OTFBJSKQ	RNF11_HUMAN	Increases Expression	[28]
Transformation/transcription domain-associated protein (TRRAP)	OT68OI2Y	TRRAP_HUMAN	Decreases Expression	[28]
Carbohydrate sulfotransferase 2 (CHST2)	OTV11IZF	CHST2_HUMAN	Decreases Expression	[28]
G-protein-signaling modulator 3 (GPSM3)	OT2MO458	GPSM3_HUMAN	Decreases Expression	[28]
U6 snRNA-associated Sm-like protein LSm4 (LSM4)	OTLKJB3A	LSM4_HUMAN	Decreases Expression	[28]
DNA-directed RNA polymerase III subunit RPC8 (POLR3H)	OT7GM7MX	RPC8_HUMAN	Decreases Expression	[28]
NEDD8 ultimate buster 1 (NUB1)	OTWA6RTX	NUB1_HUMAN	Increases Expression	[28]
Selenoprotein K (SELENOK)	OTKM7N7P	SELK_HUMAN	Increases Expression	[28]
Nuclear receptor coactivator 3 (NCOA3)	OTBX300Z	NCOA3_HUMAN	Increases Expression	[28]
Numb-like protein (NUMBL)	OTWMTMMH	NUMBL_HUMAN	Increases Expression	[28]
ATPase MORC2 (MORC2)	OT52A8BJ	MORC2_HUMAN	Increases Expression	[28]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Increases Expression	[42]
Aldo-keto reductase family 1 member B1 (AKR1B1)	OTRX72TH	ALDR_HUMAN	Increases Expression	[42]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[42]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Increases Expression	[42]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Affects Expression	[42]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Increases Expression	[42]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Increases Expression	[42]
Toll-like receptor 4 (TLR4)	OTP7ML3S	TLR4_HUMAN	Increases Expression	[43]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Decreases Expression	[44]
NF-kappa-B inhibitor epsilon (NFKBIE)	OTLAYEL9	IKBE_HUMAN	Increases Stability	[45]
Myc box-dependent-interacting protein 1 (BIN1)	OTK8O0X8	BIN1_HUMAN	Increases Expression	[33]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[46]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	OT9RDS3H	IKKB_HUMAN	Decreases Expression	[31]
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)	OTLF4ZB1	IKKA_HUMAN	Increases Expression	[31]
Apoptosis regulatory protein Siva (SIVA1)	OTDT0XZK	SIVA_HUMAN	Decreases Expression	[33]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[47]
High affinity copper uptake protein 1 (SLC31A1)	OTXLRTUB	COPT1_HUMAN	Decreases Degradation	[48]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[33]
Histone-lysine N-methyltransferase SUV39H1 (SUV39H1)	OTDTF5BU	SUV91_HUMAN	Decreases Expression	[33]
Serine protease HTRA2, mitochondrial (HTRA2)	OTC7616F	HTRA2_HUMAN	Affects Localization	[49]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Activity	[50]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Increases Expression	[51]
Toll-like receptor 2 (TLR2)	OTGO5P4R	TLR2_HUMAN	Increases Expression	[31]
DENN domain-containing protein 4B (DENND4B)	OTFEO8KG	DEN4B_HUMAN	Increases Expression	[52]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B)	OTL9I7LO	GA45B_HUMAN	Increases Expression	[52]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Increases Expression	[52]
Natural cytotoxicity triggering receptor 1 (NCR1)	OT6MZKQY	NCTR1_HUMAN	Decreases Expression	[53]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G)	OT8V1J4M	GA45G_HUMAN	Increases Expression	[47]
BAG family molecular chaperone regulator 3 (BAG3)	OTVXYUDQ	BAG3_HUMAN	Increases Expression	[52]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Affects Localization	[49]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[54]
Insulin-like growth factor II (IGF2)	OTJ4O6MW	IGF2_HUMAN	Decreases Response To Substance	[55]
Prelamin-A/C (LMNA)	OT3SG7ZR	LMNA_HUMAN	Increases Cleavage	[56]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Decreases Expression	[57]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Phosphorylation	[58]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Activity	[59]
Galectin-2 (LGALS2)	OTY08TMQ	LEG2_HUMAN	Decreases Expression	[33]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Increases Phosphorylation	[60]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[61]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[31]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Decreases Expression	[31]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Activity	[29]
Integrin alpha-V (ITGAV)	OTAM7JTR	ITAV_HUMAN	Increases Expression	[31]
Cathepsin B (CTSB)	OTP9G5QB	CATB_HUMAN	Increases Localization	[50]
Heat shock protein HSP 90-alpha (HSP90AA1)	OTLG1WPK	HS90A_HUMAN	Decreases Expression	[31]
Heat shock protein HSP 90-beta (HSP90AB1)	OTR69EG7	HS90B_HUMAN	Increases Expression	[43]
Growth-regulated alpha protein (CXCL1)	OT3WCTZV	GROA_HUMAN	Increases Expression	[52]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[52]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[62]
Heat shock 70 kDa protein 1A (HSPA1A)	OTKGIE76	HS71A_HUMAN	Increases Expression	[43]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[52]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Decreases Expression	[63]
Cytochrome c oxidase subunit 8A, mitochondrial (COX8A)	OTU0NR39	COX8A_HUMAN	Decreases Expression	[59]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[64]
Osteopontin (SPP1)	OTJGC23Y	OSTP_HUMAN	Decreases Expression	[31]
Growth hormone receptor (GHR)	OT8WUWMU	GHR_HUMAN	Increases Expression	[43]
Parathyroid hormone-related protein (PTHLH)	OTI1JF13	PTHR_HUMAN	Decreases Expression	[63]
Interferon-induced transmembrane protein 1 (IFITM1)	OTECO1G8	IFM1_HUMAN	Decreases Expression	[33]
Protein Cripto (CRIPTO)	OT46DZXJ	TDGF1_HUMAN	Increases Expression	[43]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[31]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[65]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Expression	[66]
Interleukin-1 receptor type 1 (IL1R1)	OTTU8959	IL1R1_HUMAN	Increases Expression	[43]
Transcription factor 4 (TCF4)	OTB9ASTK	ITF2_HUMAN	Increases Expression	[43]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Decreases Phosphorylation	[67]
Interleukin-7 receptor subunit alpha (IL7R)	OTBMFLQQ	IL7RA_HUMAN	Increases Expression	[31]
Heat shock 70 kDa protein 6 (HSPA6)	OTH4S7WB	HSP76_HUMAN	Increases Expression	[52]
Transcription factor JunB (JUNB)	OTG2JXV5	JUNB_HUMAN	Decreases Expression	[68]
CCAAT/enhancer-binding protein beta (CEBPB)	OTM9MQIA	CEBPB_HUMAN	Decreases Expression	[31]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Increases Expression	[31]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[47]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[52]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Decreases Expression	[69]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Affects Expression	[44]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Activity	[29]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Decreases Expression	[31]
DnaJ homolog subfamily B member 1 (DNAJB1)	OTCOSEVH	DNJB1_HUMAN	Increases Expression	[52]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Expression	[43]
Pentraxin-related protein PTX3 (PTX3)	OTPXHRKU	PTX3_HUMAN	Decreases Expression	[31]
CD27 antigen (CD27)	OTH7NA58	CD27_HUMAN	Increases Expression	[43]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Activity	[57]
Calreticulin (CALR)	OTYD2TR1	CALR_HUMAN	Increases Expression	[41]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[57]
Tyrosine-protein phosphatase non-receptor type 6 (PTPN6)	OT33XNZM	PTN6_HUMAN	Decreases Expression	[33]
SHC-transforming protein 1 (SHC1)	OT1J5IRN	SHC1_HUMAN	Decreases Expression	[31]
Nitric oxide synthase 1 (NOS1)	OT7M8XVG	NOS1_HUMAN	Increases Expression	[41]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Activity	[57]
DNA replication licensing factor MCM7 (MCM7)	OT6FXC6K	MCM7_HUMAN	Decreases Expression	[33]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Increases Expression	[70]
Replication protein A 14 kDa subunit (RPA3)	OT8JAQGL	RFA3_HUMAN	Decreases Expression	[33]
Pro-adrenomedullin (ADM)	OT7T0TA4	ADML_HUMAN	Decreases Expression	[31]
Insulin receptor substrate 1 (IRS1)	OTNO82CU	IRS1_HUMAN	Decreases Degradation	[71]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[33]
Alpha-synuclein (SNCA)	OTPWC1MR	SYUA_HUMAN	Increases Expression	[43]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Decreases Expression	[72]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[47]
Small ribosomal subunit protein eS19 (RPS19)	OTBKGP48	RS19_HUMAN	Increases Expression	[52]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[60]
Caspase-2 (CASP2)	OTUDYSPP	CASP2_HUMAN	Increases Cleavage	[52]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases Phosphorylation	[73]
Mitogen-activated protein kinase 9 (MAPK9)	OTCEVJ9E	MK09_HUMAN	Increases Phosphorylation	[73]
Proliferation marker protein Ki-67 (MKI67)	OTA8N1QI	KI67_HUMAN	Decreases Expression	[74]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[29]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Expression	[75]
Caspase-4 (CASP4)	OTVQTV1L	CASP4_HUMAN	Increases Activity	[60]
Isocitrate dehydrogenase subunit alpha, mitochondrial (IDH3A)	OT5QQB5L	IDH3A_HUMAN	Decreases Expression	[59]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Decreases Expression	[76]
Small ribosomal subunit protein mS29 (DAP3)	OTNPEZYM	RT29_HUMAN	Increases Expression	[33]
Breast cancer type 2 susceptibility protein (BRCA2)	OTF1XSV1	BRCA2_HUMAN	Decreases Expression	[72]
Interleukin-1 receptor-associated kinase 1 (IRAK1)	OT133G8J	IRAK1_HUMAN	Decreases Expression	[31]
DNA mismatch repair protein Msh6 (MSH6)	OT46FP09	MSH6_HUMAN	Decreases Expression	[33]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[77]
Caspase-6 (CASP6)	OTXLD3EC	CASP6_HUMAN	Increases Cleavage	[62]
Hepatocyte nuclear factor 3-alpha (FOXA1)	OTEBY0TD	FOXA1_HUMAN	Decreases Expression	[31]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Increases Cleavage	[47]
Histone deacetylase 4 (HDAC4)	OTQNGD32	HDAC4_HUMAN	Decreases Expression	[33]
NACHT, LRR and PYD domains-containing protein 12 (NLRP12)	OTGR132Z	NAL12_HUMAN	Increases Expression	[31]
Beta-2-microglobulin (B2M)	OTDWN6NX	B2MG_HUMAN	Decreases Expression	[78]
C-C motif chemokine 8 (CCL8)	OTCTWYN8	CCL8_HUMAN	Affects Expression	[44]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Affects Localization	[49]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Increases Expression	[43]
Nuclear factor NF-kappa-B p100 subunit (NFKB2)	OTS231V7	NFKB2_HUMAN	Decreases Expression	[69]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Cleavage	[79]
Dystonin (DST)	OTHZBM4X	DYST_HUMAN	Increases Expression	[33]
Heat shock factor protein 2 (HSF2)	OTXNJIJ9	HSF2_HUMAN	Increases Expression	[80]
DNA repair protein RAD51 homolog 1 (RAD51)	OTNVWGC1	RAD51_HUMAN	Decreases Expression	[72]
Fragile X messenger ribonucleoprotein 1 (FMR1)	OTWEV0T5	FMR1_HUMAN	Decreases Expression	[33]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[81]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[50]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Increases Cleavage	[62]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)	OT4SO7J4	BNIP3_HUMAN	Increases Expression	[56]
Baculoviral IAP repeat-containing protein 1 (NAIP)	OTLA925F	BIRC1_HUMAN	Affects Expression	[69]
Chromatin assembly factor 1 subunit A (CHAF1A)	OTXSSY4H	CAF1A_HUMAN	Decreases Expression	[33]
S-phase kinase-associated protein 2 (SKP2)	OTD5B41X	SKP2_HUMAN	Decreases Expression	[82]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Increases Cleavage	[79]
Bcl-2-interacting killer (BIK)	OTTH1T3D	BIK_HUMAN	Increases Activity	[50]
Interleukin-18 receptor 1 (IL18R1)	OT83XMPQ	IL18R_HUMAN	Increases Expression	[43]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Increases Expression	[83]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[45]
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)	OTC41R1E	RIPK1_HUMAN	Decreases Expression	[31]
Cullin-1 (CUL1)	OTXPE1UZ	CUL1_HUMAN	Increases Expression	[43]
Cullin-3 (CUL3)	OTDNOAPM	CUL3_HUMAN	Decreases Expression	[33]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Decreases Expression	[69]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Cleavage	[79]
Transcription elongation factor A protein-like 1 (TCEAL1)	OTAPG2L5	TCAL1_HUMAN	Increases Expression	[43]
Interferon regulatory factor 4 (IRF4)	OT1DHQ1P	IRF4_HUMAN	Decreases Expression	[68]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Activity	[59]
Hsp90 co-chaperone Cdc37 (CDC37)	OTYDT4A7	CDC37_HUMAN	Increases Expression	[43]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Expression	[84]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Increases Expression	[85]
Carbonic anhydrase 9 (CA9)	OTNA51XT	CAH9_HUMAN	Decreases Expression	[85]
TIR domain-containing adapter molecule 2 (TICAM2)	OTK7GIJ5	TCAM2_HUMAN	Increases Expression	[31]
Cell division cycle and apoptosis regulator protein 1 (CCAR1)	OTUXLQZZ	CCAR1_HUMAN	Increases Expression	[86]
Ectodysplasin-A receptor-associated adapter protein (EDARADD)	OT0G52MC	EDAD_HUMAN	Increases Expression	[43]
DNA-binding death effector domain-containing protein 2 (DEDD2)	OT0WXRWT	DEDD2_HUMAN	Increases Expression	[33]
Heat shock protein 105 kDa (HSPH1)	OTVRR73T	HS105_HUMAN	Increases Expression	[47]
CREB-binding protein (CREBBP)	OTPA4QGM	CBP_HUMAN	Decreases Expression	[69]
Histone acetyltransferase KAT2B (KAT2B)	OTWQITWK	KAT2B_HUMAN	Decreases Expression	[31]
Bcl-2-like protein 2 (BCL2L2)	OTMKVO0J	B2CL2_HUMAN	Increases Expression	[87]
N-alpha-acetyltransferase 80 (NAA80)	OTLWR71Z	NAA80_HUMAN	Decreases Expression	[33]
MOB kinase activator 3A (MOB3A)	OTILIOXF	MOB3A_HUMAN	Decreases Expression	[33]
Baculoviral IAP repeat-containing protein 7 (BIRC7)	OTITCGHB	BIRC7_HUMAN	Decreases Expression	[88]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3)	OTZM6MHU	NLRP3_HUMAN	Decreases Expression	[33]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Increases Expression	[89]
Tribbles homolog 3 (TRIB3)	OTG5OS7X	TRIB3_HUMAN	Increases Expression	[41]
Cell growth regulator with EF hand domain protein 1 (CGREF1)	OTBZQX97	CGRE1_HUMAN	Increases Expression	[43]
Myeloid differentiation primary response protein MyD88 (MYD88)	OTB4D6FL	MYD88_HUMAN	Decreases Expression	[31]
Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1)	OTJGE772	CHAC1_HUMAN	Increases Expression	[52]
Fanconi anemia group D2 protein (FANCD2)	OTVEB5LF	FACD2_HUMAN	Decreases Expression	[90]
Eukaryotic translation initiation factor 2A (EIF2A)	OTWXELQP	EIF2A_HUMAN	Decreases Phosphorylation	[91]
DNA replication factor Cdt1 (CDT1)	OTVY53VG	CDT1_HUMAN	Decreases Expression	[33]
Interleukin-23 subunit alpha (IL23A)	OTYO99HC	IL23A_HUMAN	Increases Expression	[43]
Transcription factor 7-like 2 (TCF7L2)	OTVWPZ8B	TF7L2_HUMAN	Increases Expression	[43]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Increases Expression	[69]
Sphingosine kinase 1 (SPHK1)	OTWYPBVD	SPHK1_HUMAN	Decreases Expression	[92]
Anaphase-promoting complex subunit 11 (ANAPC11)	OTK2SJXR	APC11_HUMAN	Decreases Expression	[33]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3)	OT0DZGY4	E2AK3_HUMAN	Increases Phosphorylation	[52]
Lipid transferase CIDEB (CIDEB)	OT873IYM	CIDEB_HUMAN	Decreases Expression	[33]
Adenine DNA glycosylase (MUTYH)	OTXTKI7Q	MUTYH_HUMAN	Decreases Expression	[33]
Cell cycle progression protein 1 (CCPG1)	OT0IHDKL	CCPG1_HUMAN	Increases Expression	[31]
FAS-associated factor 1 (FAF1)	OTGAMLM4	FAF1_HUMAN	Increases Expression	[43]
Transcription factor 19 (TCF19)	OT7NKLF9	TCF19_HUMAN	Decreases Expression	[33]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5)	OT03QCLM	ATF5_HUMAN	Increases Expression	[47]
Rho-related BTB domain-containing protein 2 (RHOBTB2)	OT2DATFX	RHBT2_HUMAN	Increases Response To Substance	[93]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Decreases Response To Substance	[94]
Palmitoyl thioesterase CPT1C (CPT1C)	OT8F1MBF	CPT1C_HUMAN	Increases Response To Substance	[93]
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (ATP2A1)	OT959A3A	AT2A1_HUMAN	Affects Response To Substance	[95]
Histone deacetylase 6 (HDAC6)	OT9W9MXQ	HDAC6_HUMAN	Decreases Response To Substance	[96]
Serine/threonine-protein kinase 4 (STK4)	OTBRYNNH	STK4_HUMAN	Increases Response To Substance	[97]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Response To Substance	[93]
Transcription factor SOX-8 (SOX8)	OTEJXYZM	SOX8_HUMAN	Increases Response To Substance	[93]
DNA repair endonuclease XPF (ERCC4)	OTFIOPG1	XPF_HUMAN	Increases Response To Substance	[93]
Polyunsaturated fatty acid lipoxygenase ALOX12 (ALOX12)	OTFL5KR5	LOX12_HUMAN	Increases Response To Substance	[93]
Heat shock protein beta-1 (HSPB1)	OTHFZ8ED	HSPB1_HUMAN	Decreases Response To Substance	[98]
Peroxisome proliferator-activated receptor delta (PPARD)	OTI4WTOP	PPARD_HUMAN	Increases Response To Substance	[93]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Response To Substance	[93]
Unconventional myosin-Va (MYO5A)	OTMWLP3E	MYO5A_HUMAN	Increases Response To Substance	[93]
Proteasome subunit beta type-5 (PSMB5)	OTOZXAS6	PSB5_HUMAN	Decreases Response To Substance	[99]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Increases Response To Substance	[100]
Mannose-binding protein C (MBL2)	OTS63HG5	MBL2_HUMAN	Increases Response To Substance	[93]
Nucleophosmin (NPM1)	OTTBYYT0	NPM_HUMAN	Increases Response To Substance	[101]
BRCA1-associated RING domain protein 1 (BARD1)	OTTC0Z9Y	BARD1_HUMAN	Increases Response To Substance	[100]
General transcription and DNA repair factor IIH helicase subunit XPB (ERCC3)	OTVAW3P1	ERCC3_HUMAN	Increases Response To Substance	[93]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Increases Response To Substance	[93]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1)	OTY9R6FZ	ERN1_HUMAN	Decreases Response To Substance	[60]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCFSMJE	OVCAR3	Investigative	[1]
Adult T acute lymphoblastic leukemia	DCVHQHI	MOLT-4	Investigative	[1]
Amelanotic melanoma	DC016ZH	M14	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DCRWWH2	CCRF-CEM	Investigative	[1]
Chronic myelogenous leukemia	DC0UFUZ	K-562	Investigative	[1]
Invasive ductal carcinoma	DC1H8MO	T-47D	Investigative	[102]
Invasive ductal carcinoma	DCERUMO	HS 578T	Investigative	[102]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
• [3] Bortezomib FDA Label
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
• [6] Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
• [7] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [8] Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012 Apr;24(4):852-8. doi: 10.1016/j.cellsig.2011.11.020. Epub 2011 Dec 8.
• [9] Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
• [10] Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
• [11] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [12] Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
• [13] Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013 Feb;41(2):343-52.
• [14] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [15] Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
• [16] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [17] Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
• [18] Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
• [19] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [20] Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
• [21] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [22] Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.
• [23] Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2.
• [24] Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
• [25] Tyrosine phosphorylation of the scaffold protein IQGAP1 in the MET pathway alters function. J Biol Chem. 2020 Dec 25;295(52):18105-18121. doi: 10.1074/jbc.RA120.015891. Epub 2020 Oct 21.
• [26] Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. Toxicol Lett. 2020 Feb 1;319:102-110. doi: 10.1016/j.toxlet.2019.11.007. Epub 2019 Nov 7.
• [27] Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
• [28] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [29] The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004 Jan;3(1):59-70.
• [30] Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther. 2008 Aug;7(8):2298-307. doi: 10.1158/1535-7163.MCT-08-0186.
• [31] Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010 Jun;199(2):110-20. doi: 10.1016/j.cancergencyto.2010.02.010.
• [32] Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci. 2010 Jun;101(6):1403-8. doi: 10.1111/j.1349-7006.2010.01544.x. Epub 2010 Mar 15.
• [33] Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res. 2008 Feb;32(2):275-85. doi: 10.1016/j.leukres.2007.05.024. Epub 2007 Jul 19.
• [34] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [35] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [36] CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.
• [37] Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8.
• [38] Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7.
• [39] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [40] Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8.
• [41] Increasing intratumor C/EBP- LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0.
• [42] Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. Chem Biol Interact. 2011 May 30;191(1-3):239-49.
• [43] Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer. 2007 Oct 22;97(8):1099-105. doi: 10.1038/sj.bjc.6604003. Epub 2007 Sep 25.
• [44] Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol. 2010 Mar;84(3):212-22. doi: 10.1111/j.1600-0609.2009.01381.x. Epub 2009 Nov 17.
• [45] Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005 Jan 13;24(3):419-30. doi: 10.1038/sj.onc.1208212.
• [46] The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003 Aug 7;22(32):4953-63. doi: 10.1038/sj.onc.1206656.
• [47] The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4706-19. doi: 10.1167/iovs.06-1147.
• [48] Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. J Ovarian Res. 2013 Nov 9;6(1):78. doi: 10.1186/1757-2215-6-78.
• [49] Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 2005 Jul 15;65(14):6294-304. doi: 10.1158/0008-5472.CAN-05-0686.
• [50] PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006 Apr 28;281(17):11923-32. doi: 10.1074/jbc.M508533200. Epub 2006 Jan 30.
• [51] Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J Biol Chem. 2010 Feb 26;285(9):6091-100. doi: 10.1074/jbc.M109.014092. Epub 2009 Dec 18.
• [52] Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004 Nov;24(22):9695-704. doi: 10.1128/MCB.24.22.9695-9704.2004.
• [53] Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica. 2009 Apr;94(4):470-8. doi: 10.3324/haematol.13783. Epub 2009 Feb 19.
• [54] PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009 May 15;15(10):3354-65. doi: 10.1158/1078-0432.CCR-08-2365. Epub 2009 May 5.
• [55] Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II. Toxicol Lett. 2013 Nov 25;223(2):109-15. doi: 10.1016/j.toxlet.2013.09.006. Epub 2013 Sep 18.
• [56] Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 2010 Jan;6(1):19-35. doi: 10.4161/auto.6.1.10323.
• [57] Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro Oncol. 2008 Jun;10(3):309-19. doi: 10.1215/15228517-2007-063. Epub 2008 Apr 29.
• [58] Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells. Cancer Sci. 2010 Oct;101(10):2220-6. doi: 10.1111/j.1349-7006.2010.01662.x. Epub 2010 Aug 5.
• [59] Identification of Compounds That Inhibit Estrogen-Related Receptor Alpha Signaling Using High-Throughput Screening Assays. Molecules. 2019 Feb 27;24(5):841. doi: 10.3390/molecules24050841.
• [60] Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 2005 Dec 15;65(24):11658-66. doi: 10.1158/0008-5472.CAN-05-2370.
• [61] Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-B activity. Exp Hematol. 2013 Feb;41(2):209-18. doi: 10.1016/j.exphem.2012.10.002. Epub 2012 Oct 11.
• [62] Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia. 2006 Jun;20(6):1017-27. doi: 10.1038/sj.leu.2404200.
• [63] A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma. Cancer Res. 2007 Dec 15;67(24):11859-66. doi: 10.1158/0008-5472.CAN-07-1701.
• [64] Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer. 2005 Aug;49(2):163-70. doi: 10.1016/j.lungcan.2005.01.006.
• [65] Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma. PLoS One. 2013 May 16;8(5):e64369. doi: 10.1371/journal.pone.0064369. Print 2013.
• [66] Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells. Mol Cancer Ther. 2008 Dec;7(12):3807-15. doi: 10.1158/1535-7163.MCT-08-0641.
• [67] Distinct Orchestration and Dynamic Processes on -H2AX and p-H3 for Two Major Types of Genotoxic Chemicals Revealed by Mass Spectrometry Analysis. Chem Res Toxicol. 2020 Aug 17;33(8):2108-2119. doi: 10.1021/acs.chemrestox.0c00104. Epub 2020 Jun 17.
• [68] The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib. Chem Biol Interact. 2023 Oct 1;384:110687. doi: 10.1016/j.cbi.2023.110687. Epub 2023 Aug 31.
• [69] Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. Turk J Haematol. 2015 Sep;32(3):206-12. doi: 10.4274/tjh.2014.0058.
• [70] Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
• [71] Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005 Oct;4(10):1533-40. doi: 10.1158/1535-7163.MCT-05-0068.
• [72] Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood. 2011 Dec 8;118(24):6368-79. doi: 10.1182/blood-2011-06-363911. Epub 2011 Sep 13.
• [73] The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res. 2008 Jun 15;68(12):4783-90. doi: 10.1158/0008-5472.CAN-07-6483.
• [74] Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 2009 Apr;8(4):959-70. doi: 10.1158/1535-7163.MCT-08-0905.
• [75] SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis. 2007 Jul;12(7):1327-38. doi: 10.1007/s10495-007-0063-y.
• [76] Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 2006 Dec;5(12):3032-41. doi: 10.1158/1535-7163.MCT-05-0474.
• [77] Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer. 2008 Apr;44(6):876-84. doi: 10.1016/j.ejca.2008.02.022. Epub 2008 Mar 14.
• [78] [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1146-50.
• [79] Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15;101(4):1530-4. doi: 10.1182/blood-2002-08-2543. Epub 2002 Sep 26.
• [80] The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes. J Biol Chem. 2014 May 2;289(18):12705-15. doi: 10.1074/jbc.M113.513242. Epub 2014 Mar 11.
• [81] Bortezomib induces apoptosis in human neuroblastoma CHP126 cells. Pharmazie. 2010 Mar;65(3):213-8.
• [82] S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol. 2008 Dec;216(4):483-94. doi: 10.1002/path.2433.
• [83] Long-term incubation with proteasome inhibitors (PIs) induces IB degradation via the lysosomal pathway in an IB kinase (IKK)-dependent and IKK-independent manner. J Biol Chem. 2013 Nov 8;288(45):32777-32786. doi: 10.1074/jbc.M113.480921. Epub 2013 Oct 1.
• [84] TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology. 2007 Mar;45(3):649-58. doi: 10.1002/hep.21555.
• [85] A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005 Aug 1;11(15):5526-33. doi: 10.1158/1078-0432.CCR-05-0081.
• [86] Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis. Mol Cell Biochem. 2011 Nov;357(1-2):83-94. doi: 10.1007/s11010-011-0878-2. Epub 2011 May 19.
• [87] [Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Oct;16(5):1016-20.
• [88] [Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):898-901.
• [89] The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression. J Biol Chem. 2010 Mar 5;285(10):6904-12. doi: 10.1074/jbc.M109.038331. Epub 2010 Jan 5.
• [90] Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009 Dec 15;69(24):9367-75. doi: 10.1158/0008-5472.CAN-09-2616.
• [91] Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008 Oct 1;112(7):2917-26. doi: 10.1182/blood-2007-12-130823. Epub 2008 Jul 18.
• [92] Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1. Biochem Biophys Res Commun. 2011 Feb 4;405(1):31-6. doi: 10.1016/j.bbrc.2010.12.111. Epub 2010 Dec 30.
• [93] Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.
• [94] Tumor cells can evade dependence on autophagy through adaptation. Biochem Biophys Res Commun. 2012 Aug 31;425(3):684-8. doi: 10.1016/j.bbrc.2012.07.090. Epub 2012 Jul 25.
• [95] Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function. Toxicol Appl Pharmacol. 2015 Feb 15;283(1):1-8. doi: 10.1016/j.taap.2014.12.015. Epub 2015 Jan 6.
• [96] Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006 Apr 1;66(7):3773-81. doi: 10.1158/0008-5472.CAN-05-2961.
• [97] Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells. Cancer Res. 2006 Jun 15;66(12):6072-9. doi: 10.1158/0008-5472.CAN-06-0125.
• [98] Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003 Oct 1;63(19):6174-7.
• [99] Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One. 2011;6(12):e27996. doi: 10.1371/journal.pone.0027996. Epub 2011 Dec 22.
• [100] Suppression of BRCA1 sensitizes cells to proteasome inhibitors. Cell Death Dis. 2014 Dec 18;5(12):e1580. doi: 10.1038/cddis.2014.537.
• [101] Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 2013 Oct;27(10):1970-80. doi: 10.1038/leu.2013.222. Epub 2013 Jul 23.
• [102] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.